Luminespib

Drug Profile

Luminespib

Alternative Names: AUY-922; NVP-AUY-922; VER-52296

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research Technology; The Institute of Cancer Research; Vernalis
  • Developer Memorial Sloan-Kettering Cancer Center; Novartis; Royal Marsden NHS Foundation Trust; Sarah Cannon Research Institute; SCRI Development Innovations; The Institute of Cancer Research; University of Texas M. D. Anderson Cancer Center; University of Toronto; Vernalis
  • Class Amides; Antineoplastics; Isoxazoles; Morpholines; Resorcinols; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Head and neck cancer
  • Suspended Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Lymphoma; Multiple myeloma; Myeloproliferative disorders; Non-small cell lung cancer; Solid tumours
  • Discontinued Pancreatic cancer

Most Recent Events

  • 25 Apr 2017 Preclinical trials in Head and neck cancer in USA (Parenteral)
  • 22 Jan 2017 M.D. Anderson Cancer Center and Novartis terminates a phase II trial due to limited response for Lymphoma (Second-line therapy or greater) in USA (NCT01485536)
  • 01 Jan 2017 Novartis terminates a phase II trial in Non-small-cell lung cancer (Metastatic disease, Late-stage disease, Recurrent, Second-line therapy or greater) due to futility data in USA, United Kingdom, Australia, France, Hong Kong, Israel, Italy, Japan, Netherlands, Norway, Poland, Singapore, South Korea, Spain, and Taiwan (NCT01646125)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top